What is the significance of minimal residual disease (MRD) as a surrogate marker in myeloma?
Shaji K. Kumar, MD
Clinical Pearls Podcast
The Use of Biosimilars in Hematology/Oncology Practice
Dr. Charles Bennett, Dr. Marc Fishman, and Dr. Kevin Knopf
Are there any concerns or precautions clinicians should be aware of when switching a patient from IV daratumumab to subcutaneous?
Saad Z. Usmani, MD, FACP
What has been the overall impact of safety and efficacy in four-drug regimens compared to three-drug regimens?
Sagar Lonial, MD, FACP
FAQ
Developments in Newly Diagnosed Multiple Myeloma:
Considerations for Improved Patient Outcomes
LIVE Webinar - June 2, 2022
12:00 PM ET - 1:00 PM ET
Earn CME/CPE/CNE Credit!
Sagar Lonial, MD, FACP
